Executive record

Julian Adams, Ph.D.

Director at Elicio Therapeutics, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:julian-adams-ph-dVersion: public-0As of: 2026-09-28

Not yet claimed9 published Claims3 sources
  • Director

Key Claims

Biography

Julian Adams is an accomplished scientist and executive with extensive experience in drug discovery and development. He served as President and Chief Scientific Officer at Clal Biotechnology Industries and President of R&D at Infinity Pharmaceuticals. He is credited with discovering Viramune (nevirapine) for HIV and played a key role in discovering Velcade for multiple myeloma. He holds a B.S. from McGill University and Ph.D. from MIT.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: President and Chief Executive Officer · Organization not publishedELTX DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ELTX DEF 14A director slate

    sec filing · Source published: Apr 9, 2025 · Retrieved: May 15, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Chair · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Nominating/Governance · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Stand Up To Cancer · Claim reviewed: May 15, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 9, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Elicio Therapeutics, Inc. · Claim reviewed: May 15, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Elicio Therapeutics, Inc. · Claim reviewed: May 15, 2026